MedTrace Logo

Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

NCT03386071 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2019-01-16

No results posted yet for this study

Summary

The dosage of trametinib for oral administration is 2mg once daily. The patient is instructed to take the trametinib oncedaily dose at approximately the same time each day, by mouth with approximately 200 mL (almost 1 cup) of water on an empty stomach, either 1 hour before or 2 hours after a meal.

Conditions

  • Progressive Metastatic Castrate Resistant Prostate Cancer

Interventions

DRUG

Trametinib 2 mg

The dosage of trametinib for oral administration is 2mg once daily.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Matthew Rettig, M.D. · Jonsson Comprehensieve Cancer Center

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03386071 on ClinicalTrials.gov